| Julie M Thomas, RPH | |
|
2302 Sheffield Rd, Aliquippa, PA 15001-2302 | |
| (724) 375-5558 | |
| Not Available |
| Full Name | Julie M Thomas |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2302 Sheffield Rd, Aliquippa, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467773937 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | RP039949L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Julie M Thomas, RPH 512 21st Street, Aliquippa, PA 15001 Ph: (724) 312-2055 | Julie M Thomas, RPH 2302 Sheffield Rd, Aliquippa, PA 15001-2302 Ph: (724) 375-5558 |
News Archive
In a new study available on the preprint server Preprints*, researchers have innovated a transparent face shield with intrinsic antimicrobial activity.
Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia University Irving Medical Center.
IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp's products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT 200 Human DNA Identification System.
Researchers from Carnegie Mellon University and the University of Pittsburgh have published research in Nature Biomedical Engineering that will drastically improve brain-computer interfaces and their ability to remain stabilized during use, greatly reducing or potentially eliminating the need to recalibrate these devices during or between experiments.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.
› Verified 3 days ago
Mrs. Antoniette Barbuto, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1230 | |
Lori Zelesnik, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 143 Turkmar Dr, Aliquippa, PA 15001 Phone: 724-775-5325 | |
Adam Andrew, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 180-085-0339 | |
Mrs. Heather Walsh, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2665 Brodhead Rd, Aliquippa, PA 15001 Phone: 724-378-4141 | |
Mr. Gino S. Cordisco, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-816-2512 Fax: 724-776-7237 | |
Douglas Kaleugher, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Aliquippa, PA 15001 Phone: 724-378-5325 Fax: 724-378-5312 | |
James Conrad Burke, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2003 Sheffield Rd, Suite B, Aliquippa, PA 15001 Phone: 724-375-1672 |